Koers Amarin Corporation plc (ADR) Xetra
Aandelen
EH3A
US0231112063
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
||
0,658 EUR | 0,00% |
|
Omzet 2024 * | 202 mln. 188 mln. | Omzet 2025 * | 215 mln. 200 mln. | Marktkapitalisatie | 284 mln. 264 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -70 mln. -65,19 mln. | Nettowinst (verlies) 2025 * | -64 mln. -59,61 mln. | EV/omzet 2024 * | 1,19 x |
Nettoliquiditeiten 2024 * | 43,92 mln. 40,9 mln. | Nettoliquiditeiten 2025 * | 159 mln. 148 mln. | EV/omzet 2025 * | 0,58 x |
K/w-verhouding 2024 * |
-3,91
x | K/w-verhouding 2025 * |
-4,15
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,48% |
Recentste transcriptie over Amarin Corporation plc (ADR)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Aaron Berg
CEO | Chief Executive Officer | 61 | 01-11-12 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 20-06-22 |
Compliance Officer | 55 | 15/11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 28-02-23 |
Odysseas Kostas
CHM | Chairman | 49 | 28-02-23 |
Keith Horn
BRD | Director/Board Member | 66 | 28-02-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,19% | 121 mld. | |
+19,91% | 114 mld. | |
+19,10% | 23,61 mld. | |
-19,80% | 20,43 mld. | |
-15,71% | 16,55 mld. | |
-13,45% | 16,45 mld. | |
-44,35% | 15,59 mld. | |
+66,67% | 15,19 mld. | |
+2,13% | 13,54 mld. |
- Beurs
- Aandelen
- Koers AMRN
- Koers EH3A